Dexcom’s Kevin Sayer talks new G7 medical trial knowledge

On the J.P. Morgan Healthcare Convention this week, Dexcom, maker of steady glucose monitoring methods, made waves after CEO Kevin Sayers introduced new medical trial knowledge from its but to be launched CGM, the G7. 

The 308 individual trial demonstrated that the G7’s imply absolute relative distinction (MARD) was 8.2% for adults and eight.1% for pediatric sufferers. The G7 was submitted to the FDA within the fourth quarter of 2021 and remains to be awaiting regulatory clearance. 

On the monetary facet, Sayers revealed the corporate is anticipated to make $2.448 billion in unaudited income for 2021, a 27% enhance from 2020. On this upcoming yr, the corporate forecasts that it’s going to usher in between $2.82 billion and $2.94 billion in whole income. 

MobiHealthNews sat down with Sayers to debate what’s subsequent for Dexcom and the way forward for diabetes care. 

MobiHealthNews: I might love to begin off with an outline of the information you introduced at J.P. Morgan and to listen to a little bit bit extra in regards to the G7. 

Sayers: We closed the yr effectively. We grew 27% for the yr, and through a pandemic time in ’20 and ’21, we hung one other billion {dollars} of income on our outcomes. And I’d problem anyone to do higher than what we have performed throughout these occasions.

Huge information out of J.P. Morgan, and a number of the issues persons are speaking to me about and asking us. We talked so much about our Dexcom One product that we launched in 4 European international locations, and that is a chance. [It’s] the primary time we have differentiated on software program as a product, as a distinct product. We have by no means performed that earlier than. And doing that we expect is a giant a part of our future. We do suppose that we are able to finally section this market into a few product strains after which be very profitable with it. …

The options of the G7 that I talked about probably the most … it is 60% smaller than our G6 and a little bit bit greater than a nickel, a little bit smaller than 1 / 4. It is actually very unnoticeable to individuals who put on it. It is a half hour heat up. … It’s nonetheless linked. It is going to be linked to everyone. However along with being interoperable and connectable, we have additionally enhanced cybersecurity right here. 

We actually have taken new expertise. Our circuit and chip within the G6 was developed method again within the 2016-17 time-frame, and cybersecurity and Bluetooth has superior considerably since then. So the brand new chips now we have on this will once more make folks really feel safer…

We have developed a brand new software program platform for this the place a few of your knowledge that usually you’d discover in our CLARITY software – that are developments over an extended time frame – goes to be out there proper within the app, and folks will due to this fact have the ability to look and see what their timing ranges for some time frame and get extra data. [It’s] simply a neater person expertise with respect to beginning up and the whole lot we have discovered. …

Then we get to the accuracy knowledge. Dexcom has all the time been one of the best. …Finger sticks of their assessments again within the day had been like 10% off from laboratory blood instrument measurements. Our imply to common relative distinction is within the low eight with this product when in comparison with a laboratory instrumentation. So we’re getting near our finger sticks with the accuracy of this. Individuals can actually depend on it to make good choices they usually’ll really feel very snug with what they’ve. [It] once more units the bar increased for everyone else.

MobiHealthNews: I do know up to now we have talked so much about perhaps increasing past simply folks with diabetes. Is that also a consideration or is that also one thing that you are looking at sooner or later?

Sayers: That could be very a lot one thing we’re taking a look at sooner or later. And now we have relationships with loads of early part corporations which are making an attempt in a certified, accredited method. To be clear, they have the correct paperwork to get folks utilizing CGM for simply well being and wellness. And the outcomes from these guys have been actually good. 

Two research I talked about in my presentation, the Onduo examine, which noticed reductions – and these had been the Sort 2 sufferers – however whenever you have a look at the mixed set of outcomes, [you see] higher cardiovascular outcomes, weight reduction, all types of issues. After which Welldoc ran a examine once more in Sort 2 sufferers, however individuals who had a median glucose above 180 on this cohort of sufferers. They used the product after 24 weeks of steady CGM, the place decreased common glucose by a median of 54 factors. So you then get into different makes use of of the expertise, metabolic stuff. Any person involved about what they’re consuming or as prediabetes approaches. How shut are you? When do you begin a compound? Possibly to cease this factor?

MobiHealthNews: I might love to speak a little bit bit extra in regards to the software program. How does Dexcom One change the sport for the long run, and notably Dexcom’s large imaginative and prescient for the long run? What sorts of capabilities are you able to foresee with including software program?

Sayers: With Dexcom One, what we did is we took options out. We made it a extra easy product that might justify a cheaper price level. And we took a number of the alerts and alarm options out. We took the flexibility to share knowledge out. We took some issues out to make it a extra easy product and extra aggressive with what’s in these marketplaces. And so sooner or later, on the software program facet … I might see a day the place now we have a menu of options that both folks can get reimbursed for, or they will select to not use if they do not need to, or they will pay for in the event that they’re extremely refined. And what I might love is a platform whereby if folks develop these options, we are able to add tiles to our personal software program and make it so you may get out and use one other app and maintain Dexcom as your hub.

MobiHealthNews: What do you see as 2022 comes down the pipeline? What are a number of the largest modifications in diabetes care that you are looking out for? And what are a number of the issues that you just foresee for Dexcom as effectively?

Sayers: One factor we would prefer to see is elevated entry all around the world to our expertise. And whereas it isn’t extremely technical, it is simply actually necessary. When this product is reimbursed and lined, folks come and get it they usually use it they usually have unimaginable experiences with it. …

I believe you may have some very thrilling developments on the pharmaceutical facet as folks maintain these new Sort 2 compounds. [They] look very thrilling and really partaking. It is going to be fascinating to see how they roll out and the place that every one shakes out throughout the drug corporations. I do know they’re all working very exhausting on these compounds they usually seem to provide superb outcomes.  

I believe the opposite factor in our world, we’re very a lot anticipating the launch of Omnipod 5 with insulin this yr. We have labored with insulin for a few years and we had been so excited to get this built-in product lastly.